Results from Late Stage Bladder Cancer Clinical Trial Conducted by SUO-CTC Are Published in the Lancet Oncology
Posted: December 2, 2020
A breakthrough therapy discovered during Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) Phase 2 and 3 trials was published by The Lancet Oncology. The Lancet Oncology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The treatment, currently with the U.S. Food and Drug Administration (FDA) has the potential to offer physicians a new option in treating bladder cancer. It also has the potential to offer hope to those suffering from the disease.
Read More